145 results about "Metabolic Marker" patented technology

The embodiment of the invention discloses a sleep peptide and differential metabolite detection method for caenorhabditis elegans, belongs to the technical field of organism metabolism, and aims to research sleep-awakening key metabolite of caenorhabditis elegans and a regulation mechanism of the sleep-awakening key metabolite. According to the sleep peptide for caenorhabditis elegans, the sleep peptide is an F4 monomer as shown in SEQ ID NO: 1. Compared with the prior art, the sleep and awakening process of the caenorhabditis elegans under the intervention of the goat milk-derived sleep peptide is analyzed through a metabonomics technology, the key metabolite for regulating and controlling sleep and awakening is successfully screened out, and a core metabolic pathway related to the key metabolite is disclosed. The application also constructs a metabolite-pathway-target regulation framework, fills the blank of sleep research in the aspect of metabolic regulation, provides a scientific basis for a sleep intervention strategy based on metabolic regulation, and also lays a foundation for developing metabolic markers of sleep states in the future.

The metabolic marker can be used for early diagnosis of heart failure, has the advantages of high sensitivity, rapidness, convenience and accurate and reliable result, provides a basis for clinical decision, provides a certain basis for subsequent fundamental research and clinical research, and has potential application and research values. The metabolic marker comprises one or more of 1-(4-nitrophenyl) piperidine, sphingolipid d19: 3 / 23: 0, phosphatidyl ethanolamine 16: 1e / 22: 5, phosphatidyl ethanolamine 16: 1e / 22: 6, sphingolipid d14: 0 / 22: 1, 3-phosphoglyceric acid, phosphatidylcholine 15: 0 / 20: 4, phosphatidylcholine o-16: 1 / 18: 0, phosphatidylcholine 14: 0e / 20: 1, phosphatidylcholine 17: 0 / 18: 5, betaine, phosphatidylcholine 15: 0 / 18: 2 and phosphatidylcholine 18: 5e / 20: 4.

The invention discloses a negative ion metabolism marker for thyroid-associated ophthalmopathy, a product and application of the negative ion metabolism marker. The metabolic marker is prepared from any one or more of 7alpha, 17alpha-dimethyl-5beta-androstane-3 alpha, 17beta-diol, N, N-dimethyl phosphatidyl ethanolamine, 15 (S)-hydroxy eicosatrienoic acid and 1-myristoyl-2-[(9Z)-octadecenoyl]-sn-glycerol-3-phosphatidylcholine, and the metabolic marker is prepared from any one or more of the following raw materials: 1-myristoyl-2-[(9Z)-octadecenoyl]-sn-glycerol-3-phosphatidylcholine. The invention provides a kit which comprises a detection reagent for detecting the negative ion metabolism marker. The invention provides a computer program product for thyroid-related eye diseases. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of thyroid-related eye diseases, and provides a new tool for clinical diagnosis.

The invention discloses a rapid detection method for bloodstream infection pathogenic bacteria based on a rapid mass spectrometry technology, and belongs to the technical field of medical detection. Analyzing the metabolic gas of the blood flow infected pathogenic bacteria by using UVP-TOFMS to obtain a pathogenic bacteria metabolic profile spectrogram; preprocessing the obtained pathogenic bacterium metabolism profile spectrogram data; integrating the preprocessed pathogenic bacterium metabolism profile spectrogram data by using a stacking algorithm, and constructing a pathogenic bacterium identification model; evaluating the effectiveness of the pathogenic bacterium identification model on a training set and a test set through accuracy, precision, a confusion matrix and a subject operation curve; and comparing and screening characteristic metabolic markers of the pathogenic bacteria by combining the importance and significance of model characteristics, and indicating the types of the pathogenic bacteria. The method does not need sample pretreatment, is simple and convenient to operate, short in detection time (20 seconds per sample), high in accuracy and suitable for clinical popularization, and provides technical support for early diagnosis and treatment of bloodstream infection.

The invention belongs to the technical field of teenager depression marker detection, and particularly relates to a teenager depression marker detection kit and a teenager depression marker detection method, the kit comprises an extraction liquid, an internal standard substance, a quality control substance and a mobile phase additive, the internal standard substance comprises a stable isotope labeled metabolic marker, the quality control substance comprises a standard metabolic marker, and the mobile phase additive comprises a mobile phase. The detection method comprises the following steps: S1, dissolving an internal standard substance by using a methanol-containing aqueous solution to prepare an internal standard stock solution; s2, methanol is added into the internal standard stock solution for dilution, uniform mixing is performed, and an extraction working solution is prepared; s3, taking a quality control product / sample, adding an extraction working solution, carrying out oscillation incubation, centrifuging, and taking supernate as a to-be-detected sample; s4, the sample to be detected is detected through a liquid chromatograph-mass spectrometer, various biomarkers related to depression in the body of the teenager can be rapidly and accurately detected, and an objective and reliable basis is provided for early diagnosis and illness state evaluation of the depression of the teenager.

The invention discloses a specific metabolic marker combination for diagnosing ovarian cancer and application thereof, and belongs to the field of markers for detecting ovarian cancer. The invention discloses a specific metabolic marker combination for diagnosing ovarian cancer. The specific metabolic marker combination comprises phosphatidylcholine 36: 6, sphingomyelin d40: 2 and sphingomyelin d41: 2. According to the invention, a metabonomics technology is used to screen out a specific metabolism marker combination for diagnosing ovarian cancer, and the specific metabolism marker combination has high sensitivity in ovarian cancer diagnosis and has high diagnosis capability for ovarian cancer diagnosis. The specific metabolic marker combination also has high specificity in ovarian cancer diagnosis, but is not applicable to diagnosis of endometrial cancer and cervical cancer. In addition, the plasma sample acquisition mode has the advantages of non-invasiveness and convenience, and has a wide application prospect in the research of biomarkers.

This invention belongs to the field of diagnostic testing technology. Addressing the problem that existing gestational diabetes screening methods may miss the optimal time for early intervention, leading to the failure to promptly detect and manage some potentially hyperglycemic pregnant women, increasing the risk of adverse maternal and fetal outcomes, this invention proposes a plasma metabolic biomarker for the early diagnosis or prediction of gestational diabetes and its application. This plasma metabolic biomarker is at least one of L-lysine, propargylglycine, N6-acetyl-L-lysine, cyclic leucine, and glycine-deoxycholic acid. The five plasma metabolic biomarkers provided by this invention can be applied to the early diagnosis or prediction of gestational diabetes, and are of great significance for the prevention or treatment of gestational diabetes.

The invention provides a metabolic marker for auxiliary diagnosis of schizophrenia, a construction method and application. Wherein the metabolic marker comprises lysophosphatidylcholine (LPC) (17: 0 / 0: 0), oleamide, lysophosphatidyl ethanolamine LysoPE (18: 0 / 0: 0), palmitamide, lysophosphatidyl ethanolamine LysoPE (0: 0 / 20: 4), lysophosphatidyl ethanolamine LysoPE (22: 6 / 0: 0), p-methylphenol sulfate, lactic acid, 3-hydroxybutyric acid, lysophosphatidyl ethanolamine LysoPE (18: 2 / 0: 0), lysophosphatidyl ethanolamine LysoPE (16: 0 / 0: 0) and sphingosine 1-phosphate. By utilizing the metabolic marker, auxiliary diagnosis of schizophrenia can be rapidly and accurately completed in the early stage of disease attack.

The invention relates to the field of biomarkers, and particularly provides a polycystic ovarian syndrome pregnancy outcome diagnosis marker and application thereof. According to the present invention, the endometrial targeting metabonomics research is adopted to screen the disease-related potential metabolic markers such as N-Acetylaspartic acid, Suberic acid and isoallolithocholic acid, and the three metabolites are subjected to quantitative detection so as to accurately predict the pregnancy outcome of the polycystic ovarian syndrome patient, such that the pregnancy outcome of the polycystic ovarian syndrome patient can be accurately predicted, and the prediction of the pregnancy outcome of the polycystic ovarian syndrome patient can be easily achieved, such that the disease-related potential metabolic markers such as N-Acetylaspartic acid, suberic acid and isoallolithocholic acid can be provided. A new path is provided for early intervention of the disease state to improve the pregnancy outcome, and a new drug target is provided for evaluation of the endometrial function of the polycystic ovarian syndrome.

This invention provides a combination of metabolic biomarkers for T-staging assessment of colorectal cancer, comprising four groups of metabolite combinations specifically distinguishing different T stages of colorectal cancer, each group containing 10 endogenous small molecule metabolites. This invention also provides detection methods and applications for the above-mentioned metabolic biomarker combinations. Furthermore, this invention provides a method for T-staging colorectal cancer for non-diagnostic and therapeutic purposes, as well as a combination of metabolic biomarkers related to the evolution of T-staging and tumor invasion depth in colorectal cancer. The advantages of this invention are: by combining iEESI-MS detection with multivariate statistics and machine learning, specific metabolic biomarkers related to T-staging of colorectal cancer are screened, a T-staging discrimination model is constructed, and objective, accurate, and rapid assessment of T-staging of colorectal cancer is achieved, providing molecular support for preoperative individualized treatment.

The invention discloses an excrement metabolism marker for predicting spontaneous premature delivery based on UHPLC-MS (Ultra High Performance Liquid Chromatography-Mass Spectrometry) and application, and belongs to the technical field of biological medicines. According to the premature pregnant woman excrement metabolite specific biomarker and the application thereof, the premature pregnant woman excrement metabolite specific biomarker is screened out through a non-targeted metabonomics technology, and the marker is 1-hydroxyl vitamine d2, Mirtazapine n-oxide, Tetraethene glycol or a combination of the 1-hydroxyl vitamine d2, the Mirtazapine n-oxide and the Tetraethene glycol. A premature delivery prediction model established by using the marker is high in sensitivity and good in specificity, and a reference basis is provided for early prediction and accurate prevention of spontaneous premature delivery.

The application relates to application of phosphatidylinositol and phosphatidylglycerol as metabolic markers for predicting intracranial atherosclerosis progression, and belongs to the technical field of medical biological detection. In the scheme, single-sample MR analysis is carried out by combining RICAS cohort data with external database data, causal correlation between metabolites and ICAS is analyzed, and serum biomarkers phosphatidylinositol PI 18:0 / 22:6 and phosphatidylglycerol PG 18:1 / 18:2 for ICAS occurrence and development are screened out by combining characteristic metabolic changes of ICAS with causal correlation analysis. ICAS progression is collected through prospective follow-up of the RICAS cohort, the correlation between the serum biomarkers and the ICAS progression is established, and it is verified that the serum biomarkers have transformation application value and can be used as a new biomarker for early prediction of ICAS progression and derivation.

The invention relates to the technical field of nephritis medicine, in particular to an AAGN disease metabolism marker, a kit and application of the AAGN disease metabolism marker. In the blood or urine metabolism marker, the blood metabolism marker is prepared from one or more of 6-methyl nicotinamide, hypo-sulphosarcosine, guanosine, allopurinol, 8-hydroxy-2 '-deoxyguanosine, triglyceride or lysophosphatidylcholine; the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl-leucyl-phenylalanine, alloandrosterone, enterodiphenol and p-coumarin, and the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl- The metabolic marker combination and the kit are used for evaluating the disease activity state of a patient suffering from ANCA-related glomerulonephritis (AAGN), and have good repeatability, stability and biological correlation.

The application discloses that 5-oxoproline can be used as a biomarker for diagnosing chemotherapy-induced cardiomyopathy, and for the first time provides a blood metabolic marker for assisting in predicting and early diagnosing chemotherapy drug-induced cardiomyopathy, which has high accuracy and diagnostic reference value. By accurately determining the content of the small molecule metabolic marker 5-oxoproline in blood, the diagnosis of early myocardial injury induced by chemotherapy drugs will no longer completely rely on conventional non-specific myocardial injury markers and imaging methods, but will rely on the content change of metabolic products in the blood of patients as an objective index, thus advancing the time window for discovering subclinical myocardial injury, significantly improving the early diagnosis detection rate, simplifying the diagnosis process, providing an opportunity for early intervention, helping to prevent or reverse the further aggravation of chemotherapy-induced cardiomyopathy, and thus improving the overall survival prognosis of tumor patients.

The invention discloses a metabolic marker aldosterone for screening heat stress Hu sheep as well as a screening method and application thereof, and belongs to the technical field of livestock serum markers. The metabolic marker for screening the heat stress Hu sheep is aldosterone; the screening method comprises the following steps: (1) taking blood of known heat-sensitive Hu sheep or heat-resistant Hu sheep as a standard test sample, taking blood of Hu sheep to be detected as a detection sample, and centrifuging to obtain a serum sample; (2) detecting the aldosterone concentration in the serum sample; and (3) calculating the aldosterone concentration average value of the standard test sample, taking the calculated aldosterone concentration critical value as a reference level, if the aldosterone concentration of the detection sample is higher than the reference level, determining that the detection sample is a heat-resistant Hu sheep, and if the aldosterone concentration of the detection sample is lower than the reference level, determining that the detection sample is a heat-sensitive Hu sheep. The aldosterone is used as the marker for detection, has the characteristics of high accuracy and high sensitivity, and can be directly used as an evaluation index for distinguishing the heat-sensitive Hu sheep from the heat-resistant Hu sheep.

This invention discloses a method and system for embryo quality detection, relating to the field of embryo detection technology, including the following steps: S1: fertilized embryos are continuously cultured in an in vitro culture system containing specific metabolic marker detection components, and continuous dynamic imaging of the embryos is performed to obtain a complete dynamic developmental image sequence; S2: the dynamic developmental image sequence is segmented, and temporal developmental features are captured, identifying key time points such as pronucleus appearance and disappearance, cleavage, and blastocyst formation, and generating a segmentation mask corresponding to each frame of the dynamic developmental image sequence; this invention achieves full-process time-difference imaging to capture the temporal features of embryonic development, without trauma or interference, avoiding subjective bias in static observation; by segmenting the dynamic developmental image sequence and capturing temporal developmental features, the segmentation accuracy is high and the anti-interference ability is strong.

Disclosed are the use of a metabolic marker in the preparation of a product for monitoring PB neurotoxicity and a product thereof, which can be used for the early diagnosis of PB neurotoxicity with high sensitivity, rapidity, convenience, and accurate and reliable results. The metabolic markers include LysoPE 20:4 / 0:0, creatine, SM d18:1 / 24:0, SM d18:0 / 24:1, LysoPC 18:0, palmitoyl sphingomyelin, phosphocholine, PC 14:0 / 22:1, creatinine, PC 18:3 / 16:0, SM d18:1 / 16:0, sphingosine, choline, LysoPC 18:1, L-carnitine, palmitic acid, PC 18:0 / 20:4, 3-hydroxy-2-octylglutaric acid, L-acetylcarnitine, LysoPC 20:4, LysoPC 16:0, and PC 20:1 / 14:1.

The invention provides application of a metabolic marker in pulmonary fibrosis diagnosis or prognosis evaluation, and belongs to the technical field of biological medicine. Systematic analysis of metabonomics discovers that lipid metabolism of a patient suffering from pulmonary fibrosis is remarkably changed, downstream products Palmitoyl ethanolamide and 2-amino-1, 3, 4-octadecantool of lipid metabolism can be used as potential biomarkers for diagnosing pulmonary fibrosis, and objective quantitative indexes are provided for diagnosis and prognosis evaluation of pulmonary fibrosis. The invention proves that the Palmitoyl ethanolamide and the 2-amino-1, 3, 4-octadecantool are obviously related to the lung function injury degree and the concentration of the acute-stage blood inflammation marker of the pulmonary fibrosis patient, and the related characteristics prove that the Palmitoyl ethanolamide and the 2-amino-1, 3, 4-octadecantool can be used as the biomarker for evaluating the prognosis of the patient.

The invention relates to the technical field of liquid chromatography / mass spectrometry analysis, and discloses a method for improving LC / MS analysis sensitivity, which is suitable for detecting trace lipid metabolites (containing isomeride) of a biological sample. The core technical scheme is as follows: a magnetic molecularly imprinted polymer-solid phase support liquid-liquid extraction secondary purification system is adopted to remove matrix impurities, a gradient mobile phase containing a composite additive is matched to optimize separation, and the detection specificity is improved by an ion mobility spectrometry-segmented selective ion monitoring combined mode; and a stable isotope internal standard is synchronously introduced to correct quantitative deviation. Experiments show that the LOD of the method is as low as 0.12-0.25 ng / mL, the matrix effect is smaller than or equal to 5%, the separation degree and the recovery rate are excellent, low-abundance metabolic marker differences can be accurately captured, and a support is provided for disease diagnosis and metabonomics research.

The present invention discloses a hair metabolite marker combination for diagnosing Alzheimer's disease and its application. The hair metabolite marker combination includes triacontanes, erucic acid, heneicosane, behenic acid, tetracosane, 3-hydroxybutyric acid, 15-methylhexadecanoic acid, arachidic acid, heptadecanoic acid, melatonin, stearic acid, tetracosanoic acid, heneicosanoic acid, and docosane. The present invention uses metabolomics methods to study, compare, and analyze the hair metabolites of AD patients, MCI patients, and cognitively normal subjects, explores potential biomarkers that may be contained therein, obtains a group of hair metabolite differences among AD patients, and evaluates the sensitivity and specificity of this group of substances for diagnosing AD. The present invention provides a new marker for the accurate diagnosis of AD and can be used in clinical auxiliary diagnosis of AD to improve diagnostic accuracy.

The application discloses a metabolic marker, a screening method and application related to gout combined with uric acid nephrolithiasis, and belongs to the technical field of biology. The application analyzes the significant differences of metabolic small molecules in the serum of asymptomatic hyperuricemia and gout combined with uric acid nephrolithiasis patients through a metabolomics method, screens metabolic markers that can be used for predicting gout combined with uric acid nephrolithiasis, and further verifies the sensitivity, specificity and accuracy of the metabolic markers. These findings not only provide markers for early diagnosis and precise treatment of gout combined with uric acid nephrolithiasis, but also provide important basis for understanding the clinical heterogeneity of hyperuricemia and the evolution mechanism thereof.

The invention relates to the technical field of biologic detection of metabolomics, in particular to an OSAHS metabolism marker, a diagnosis model and application of the OSAHS metabolism marker and the diagnosis model. The metabolic marker comprises a red blood cell metabolite and / or a plasma metabolite; erythrocyte metabolites comprise L-aspartic acid, D-ribose-5-diphosphoric acid, cadaverine, 12, 13-epoxy octadecenoic acid, L-arginine, N-acetylmethionine, 5-hydroxyeicosatetraenoic acid, 13-oxo-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 10-tetrahydroxy-9Z, the component A is one or more of 11E-octadecadienoic acid, inosine monophosphate, nicotinamide, alpha-lactose, sphingosine, hydroxy octadecadienoyl or glyceraldehyde-3-phosphoric acid; the plasma metabolite is prepared from one or more of fumaric acid, cadaverine, L-aspartic acid, malic acid, sphingosine-1-phosphoric acid, L-arginine, cysteine-S-sulfate, thiosulfate, gamma-glutamyl alanine, galacturonic acid or vitamin B2.

This invention relates to an early selection and evaluation method for salt tolerance in grass carp based on serum metabolic markers. The method includes: (1) calculating the salinity sensitivity coefficient based on the serum metabolic markers obtained through screening: SSC = (normal control group index value - salinity treatment group index value) / normal control group index value, the larger the value, the more sensitive the fish; (2) calculating the fuzzy membership index based on the SSC value; (3) calculating the weight coefficient of each serum metabolic marker based on principal component analysis. w =Contribution rate of a single indicator / Cumulative contribution rate of principal components; (4) Calculate the comprehensive evaluation value of grass carp's salinity sensitivity based on fuzzy membership index and serum metabolic marker weight coefficient; (5) Salt tolerance assessment: In the early salt tolerance assessment, the higher the comprehensive evaluation value of salinity sensitivity, the worse the salt tolerance. This method can achieve accurate assessment of grass carp's salinity sensitivity by detecting and analyzing the dynamic changes of specific serum metabolic markers.

Disclosed in the present invention are a sphingolipid metabolic marker, an analysis method therefor and a use thereof. The sphingolipid metabolic marker can be effectively used for early diagnosis, course monitoring and prognosis assessment of asthma, and has the advantages of high sensitivity, rapidness, convenience and accurate and reliable result. The sphingolipid metabolic marker at least comprises one of the following substances: galactosylceramide d18:1 / 16:0 and galactosylceramide d18:1 / 14:0.

The invention relates to the technical field of biological medicine, and discloses a biomarker for predicting COPD cognitive impairment and application of the biomarker. The invention finds and verifies that the specificity of stearic acid (SA) in serum and a key enzyme ELOVL6 synthesized by the stearic acid (SA) in serum in a patient with secondary cognitive impairment (CI) of chronic obstructive pulmonary disease (COPD) is improved for the first time, the level of the stearic acid (SA) and the key enzyme ELOVL6 is negatively correlated with the cognitive impairment degree, and the stearic acid (SA) and the key enzyme ELOVL6 have good prediction efficiency (AUCgt, 0.82) on the COPD-CI. On the basis, the invention provides the application of the serum SA and / or ELOVL6 as the biomarker for predicting the COPD secondary CI risk, the in-vitro diagnostic kit comprising the detection reagent of the biomarker, and the method for predicting the risk by detecting the level of the marker. The invention provides a brand-new and reliable metabolic marker tool for early warning and intervention of CI of COPD patients, and has important clinical value and transformation prospect.

The application discloses a negative ion metabolic marker related to adolescent depression, a product and an application. The metabolic marker comprises any one or several of the following: Homogentisic acid, Aurantio-obtusin, 3-o-acetyl-16alpha-hydroxytrametenolic acid, Leoidin and Kynurenic acid. The application provides a kit comprising detection reagents for detecting the negative ion metabolic marker. The application provides a computer program product related to adolescent depression. The product provided by the application has good feasibility and accuracy, can effectively evaluate the risk of adolescent depression, and provides a new tool for clinical diagnosis.

The invention provides application of a group of plasma metabolism markers in preparation of a reagent product for pulmonary nodule diagnosis, and relates to the technical field of disease diagnosis reagents. The metabolic marker is prepared from trigonelline, 4-methylcatechol, 2, 4-dinitrophenol, 3, 4-dihydroxyphenylacetic acid, N-(2-furfuryl) glycine, mevalonic acid and formononetin, and the metabolic marker is prepared from the following raw materials: the trigonelline, the 4-methylcatechol, the 2, 4-dinitrophenol, the 3, 4-dihydroxyphenylacetic acid, the N-( According to the application, ultra-high performance liquid chromatography-high resolution mass spectrometry (UPLC / MS) is adopted to carry out metabonomics analysis on plasma samples before and after an early pulmonary nodule operation, and a group of plasma metabolites (trigonelline, 4-methylcatechol, 2, 4-dinitrophenol, 3, 4-dihydroxyphenylacetic acid, N-(2-furfuryl) glycine, mevalonic acid and formononetin) are identified; and the group of metabolites is utilized to form a diagnosis model, so that benign and malignant pulmonary nodules can be accurately diagnosed, and early-stage differential diagnosis and risk assessment are facilitated.

The invention relates to the technical field of metabonomics analysis, in particular to application of a metabolic marker in preparation of a head and neck squamous cell carcinoma diagnostic product, a kit, a screening method of the metabolic marker of the head and neck squamous cell carcinoma, a diagnostic model and a construction method and application of the diagnostic model. The metabolic marker comprises at least one of lactic acid, sphingosine, cadaverine, uridine diphosphate, allantoic acid, hydroxyproline, sphingosine-1-phosphoric acid, indole-3-acetaldehyde, pantothenic acid, fumaric acid, malic acid, prostaglandin or ornithine in red blood cells and / or plasma. The screened red blood cells and plasma metabolism markers can be used for predicting or diagnosing the head and neck squamous cell carcinoma respectively or independently, particularly, the red blood cell metabolism markers can provide more stable tumor microenvironment information, and the metabolism stability is high and is not easily influenced by diet and circadian rhythm.

The invention discloses a preparation method and application of a porous PtCu alloy nano material, and relates to the technical field of biology. The preparation method comprises the following steps: synthesizing a porous PtCu nano-particle micelle by adopting an improved soft template guiding method, centrifuging, washing and drying to obtain a porous PtCu nano-material; the porous PtCu alloy nano material is applied to LDI MS metabolite detection, a CAP patient plasma metabolism fingerprint spectrogram is obtained, and machine learning is carried out to construct a model. The porous PtCu alloy nano material is synthesized and applied to a laser desorption ionization mass spectrometry technology to enhance the signal sensitivity of the porous PtCu alloy nano material, the plasma metabolism fingerprint spectrum of a CAP patient is obtained through the platform, and severe CAP diagnosis and metabolic marker screening are carried out.